According to the results of network pharmacology, several key molecules (MAPK1, MAPK3, MAPK14, TP53, STAT3, CDKN1A, JUN, RELA, FOS, ESR1, IL6, and MYC) and pathways (MAPK signaling pathway, p53 signaling pathway, Apoptosis, Cell cycle and so on) were predicted to be underlying molecular mechanisms of ECD in CRC treatments. Here, MYC is linked to colorectal carcinoma.